Equities research analysts expect Sophiris Bio Inc (NASDAQ:SPHS) to post earnings per share of ($0.09) for the current quarter, according to Zacks. Zero analysts have issued estimates for Sophiris Bio’s earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.12). Sophiris Bio posted earnings of ($0.11) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 18.2%. The firm is expected to issue its next quarterly earnings results on Monday, May 13th.
According to Zacks, analysts expect that Sophiris Bio will report full year earnings of ($0.35) per share for the current year, with EPS estimates ranging from ($0.53) to ($0.25). For the next year, analysts expect that the business will post earnings of ($0.49) per share, with EPS estimates ranging from ($0.73) to ($0.33). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Sophiris Bio.
SPHS has been the topic of several recent analyst reports. Piper Jaffray Companies dropped their target price on Sophiris Bio to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 13th. Maxim Group set a $6.00 target price on Sophiris Bio and gave the stock a “buy” rating in a research report on Monday, December 17th. HC Wainwright dropped their target price on Sophiris Bio from $10.00 to $3.50 and set a “buy” rating on the stock in a research report on Thursday, March 14th. Finally, ValuEngine upgraded Sophiris Bio from a “hold” rating to a “buy” rating in a research report on Thursday, December 13th.
Several large investors have recently made changes to their positions in SPHS. Virtu Financial LLC purchased a new stake in shares of Sophiris Bio during the 4th quarter worth approximately $30,000. Geode Capital Management LLC boosted its stake in shares of Sophiris Bio by 14.9% during the 4th quarter. Geode Capital Management LLC now owns 243,523 shares of the biopharmaceutical company’s stock worth $202,000 after acquiring an additional 31,579 shares in the last quarter. Finally, Hikari Power Ltd boosted its stake in shares of Sophiris Bio by 18.2% during the 4th quarter. Hikari Power Ltd now owns 200,900 shares of the biopharmaceutical company’s stock worth $167,000 after acquiring an additional 30,900 shares in the last quarter. 8.57% of the stock is currently owned by institutional investors and hedge funds.
About Sophiris Bio
Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.
Featured Article: What Are Cryptocurrencies?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.